Cancer stem cell-specific scavenger receptor 36 drives glioblastoma progression

Stem Cells

Volumn 32, Issue 7, 2014, Pages 1746-1758

  Hale, James S ^a   Otvos, Balint ^a   Sinyuk, Maksim ^a   Alvarado, Alvaro G ^a,c   Hitomi, Masahiro ^a,c   Stoltz, Kevin ^a   Wu, Qiulian ^a   Flavahan, William ^a   Levison, Bruce ^a   Johansen, Mette L ^a   Schmitt, David ^a   Neltner, Janna M ^b   Huang, Ping ^a   Ren, Bin ^d   Sloan, Andrew E ^e,f   Silverstein, Roy L ^d   Gladson, Candece L ^b,c,f   Didonato, Joseph A ^a   Brown, J Mark ^a   McIntyre, Thomas ^a   Hazen, Stanley L ^a   Horbinski, Craig ^b   Rich, Jeremy N ^a,c,f   Lathia, Justin D ^a,c,f   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Glioma; Self renewal; Stem cell microenvironment interactions

Indexed keywords

ALPHA6 INTEGRIN; CD36 ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, CD36; BRAIN NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; KAPLAN-MEIER ESTIMATE; LIPOPROTEINS, LDL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84902578963     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1716     Document Type: Article

References (73)

1. Lawrence YR, Mishra MV, Werner-Wasik M, et al. Improving prognosis of glioblastoma in the 21st century: Who has benefited most? Cancer 2012; 118: 4228-4234.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-15183.
4. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
5. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
6. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
7. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23: 9392-9400.
8. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
9. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
12. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
13. Lathia JD, Heddleston JM, Venere M, et al. Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011; 8: 482-485.
14. Spradling A, Drummond-Barbosa D, Kai T,. Stem cells find their niche. Nature 2001; 414: 98-104.
15. Visvader JE, Lindeman GJ,. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
16. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-927.
17. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
18. Lu Z, Elliott MR, Chen Y, et al. Phagocytic activity of neuronal progenitors regulates adult neurogenesis. Nat Cell Biol 2011; 13: 1076-1083.
19. Greenberg ME, Li XM, Gugiu BG, et al. The lipid whisker model of the structure of oxidized cell membranes. J Biol Chem 2008; 283: 2385-2396.
20. Silverstein RL, Febbraio M,. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009; 2: re3.
21. Husemann J, Loike JD, Anankov R, et al. Scavenger receptors in neurobiology and neuropathology: Their role on microglia and other cells of the nervous system. Glia 2002; 40: 195-205.
22. Woo MS, Wang X, Faustino JV, et al. Genetic deletion of CD36 enhances injury after acute neonatal stroke. Ann Neurol 2012; 72: 961-970.
23. Kaur B, Cork SM, Sandberg EM, et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009; 69: 1212-1220.
24. Klenotic PA, Huang P, Palomo J, et al. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010; 176: 2039-2050.
25. Rege TA, Stewart J, Jr., Dranka B, et al. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009; 218: 94-103.
26. Anderson JC, Grammer JR, Wang W, et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007; 6: 454-462.
27. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-432.
28. Eyler CE, Wu Q, Yan K, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011; 146: 53-66.
29. Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011; 19: 498-511.
30. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
31. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274: 19055-19062.
32. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105: 1095-1108.
33. Fieser LR, Brown RH,. Synthesis of naphthoquinones for studies of the inhibition of enzyme systems. J Am Chem Soc 1949; 71: 3609-3614.
34. Still WC, Kahn M, Mitra A,. Rapid chromatographic technique for preparative separations with moderate resolution. J Org Chem 1978; 43: 2923-2925.
35. Kametani T, Nemoto H, Takeuchi M, et al. Studies on the syntheses of heterocyclic compounds. Part 681. A novel alkylation in the 4-position of isoquinoline derivatives. J Chem Soc Perkin 1 1977; 4: 386-390.
36. Coll G, Morey J, Costa A, et al. Direct lithiation of hydroxyaromatics. J OrgChem 1988; 53: 5345-5348.
37. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
38. DeFilippis RA, Chang H, Dumont N, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov 2012; 2: 826-839.
39. Tsuchida T, Kijima H, Tokunaga T, et al. Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int J Oncol 1999; 14: 47-51.
40. Hale JS, Li M, Sinyuk M, et al. Context dependent role of the CD36-thrombospondin-histidine-rich glycoprotein axis in tumor angiogenesis and growth. PLoS One 2012; 7: e40033.
41. Coraci IS, Husemann J, Berman JW, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 2002; 160: 101-112.
42. El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med 2003; 197: 1657-1666.
43. Ito D, Imai Y, Ohsawa K, et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998; 57: 1-9.
44. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
45. Qiao L, Zou C, Shao P, et al. Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. J Biol Chem 2008; 283: 8788-8795.
46. Rahaman SO, Lennon DJ, Febbraio M, et al. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006; 4: 211-221.
47. Miao WM, Vasile E, Lane WS, et al. CD36 associates with CD9 and integrins on human blood platelets. Blood 2001; 97: 1689-1696.
48. Gangemi RM, Griffero F, Marubbi D, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-48.
49. Eyler CE, Foo WC, LaFiura KM, et al. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008; 26: 3027-3036.
50. Sherry MM, Reeves A, Wu JK, et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27: 2383-2392.
51. Muller WE, Thakur NL, Ushijima H, et al. Matrix-mediated canal formation in primmorphs from the sponge Suberites domuncula involves the expression of a CD36 receptor-ligand system. J Cell Sci 2004; 117: 2579-2590.
52. Boullier A, Gillotte KL, Horkko S, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000; 275: 9163-9169.
53. Bredel M, Bredel C, Juric D, et al. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 2005; 65: 4088-4096.
54. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
55. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005; 102: 5814-5819.
56. Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia 2012; 60: 502-514.
57. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-1272.
58. Flavahan WA, Wu Q, Hitomi M, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013; 16: 1373-1382.
59. Hjelmeland AB, Wu Q, Heddleston JM, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-840.
60. Keller JN, Hanni KB, Kindy MS,. Oxidized high-density lipoprotein induces neuron death. Exp Neurol 2000; 161: 621-630.
61. Sugawa M, Ikeda S, Kushima Y, et al. Oxidized low density lipoprotein caused CNS neuron cell death. Brain Res 1997; 761: 165-172.
62. Li HL, Wang AB, Zhang R, et al. A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative Fas/Fas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RAW264.7 macrophages. J Cell Physiol 2006; 208: 307-318.
63. Hjelmeland AB, Wu Q, Wickman S, et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 2010; 8: e1000319.
64. Zamanian-Daryoush M, Lindner D, Tallant TC, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 2013; 288: 21237-21252.
65. Vlashi E, Lagadec C, Vergnes L, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011; 108: 16062-16067.
66. Guo D, Prins RM, Dang J, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009; 2: ra82.
67. Guo D, Hildebrandt IJ, Prins RM, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009; 106: 12932-12937.
68. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5-16.
69. Aguirre A, Rubio ME, Gallo V,. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature 2010; 467: 323-327.
70. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. New Engl J Med 2009; 361: 1173-1178.
71. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med 2009; 361: 1164-1172.
72. Sheridan C,. Genentech obtains proof of concept for hedgehog inhibition. Nat Biotechnol 2009; 27: 968-969.
73. Singh BN, Fu J, Srivastava RK, et al. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS One 2011; 6: e27306.